Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT03273322
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 105 participants
- Registry
-
NCT03273322
-
- Other papers using this trial's data
- Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT03273322. Randomized; no masking; primary purpose treatment. Start 2017-09-13 (actual); primary completion 2018-11-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
- Acronym
- ADRIFT
- Condition
- Atrial Fibrillation
- Condition
- Atrial Appendage
- Condition
- Hemorrhage
- Intervention (Drug)
- Rivaroxaban 10 mg qd
- Intervention (Drug)
- Rivaroxaban 15 mg qd
- Intervention (Drug)
- DAPT
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Action Research Group
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct03273322- Content hash
d1bc60eceb235ce87cb6b08189ab173fbef7e932961ec8f8d7d6d9ddd7ce8269